Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older.
- People diagnosed with hepatocellular carcinoma (a type of liver cancer) or intrahepatic cholangiocarcinoma (a type of bile duct cancer), confirmed either through standard liver association guidelines or through a tissue biopsy.
- People whose cancer has been assessed as suitable for a procedure that delivers treatment directly through the arteries of the liver — either chemoembolization (TACE) or radioembolization (TARE) — and who have not previously had that same type of procedure (confirm with trial site for details on prior treatments).
- For people being considered for TACE: liver function must meet a certain threshold (Child-Pugh score below B8), the cancer may be a single tumour or multiple tumours, there must be no major blockage of the portal vein, and no widening of the bile ducts.
- For people being considered for TARE: there must be no tumour invasion of the main portal vein trunk, the tumour must generally be confined to one side of the liver (with an exception for certain centrally located bile duct cancers), and bilirubin levels must be below a certain level (confirm with trial site).
- People covered by a social security or health insurance scheme.
- People who have read and signed the trial's informed consent form.
Who may not be able to join:
- People for whom the procedure would be technically too difficult or not possible based on their anatomy.
- People for whom a combined same-day treatment is planned alongside the trial procedure (for example, having TACE and a tumour ablation on the same day); treatments carried out on separate days are generally permitted.
- People with severe chronic kidney disease (kidney filtration rate below 30 ml/min).
- People with a known allergy to contrast dye or chemotherapy agents used in the procedure.
- People who would not be able to safely manage outpatient (day procedure) care — for example, those who could not follow discharge instructions, do not have reliable phone access, would not have a responsible adult with them on the first night after discharge, or could not reach urgent medical care quickly if needed.
- People who have already been enrolled in this trial previously.
- People who, due to psychological, social, family, or geographical reasons, would not be able to attend regular follow-up appointments.
- People with a serious uncontrolled medical condition or clinical situation.
- People with a severe uncontrolled infection.
- People who are pregnant, breastfeeding, or in labour.
- People who are currently detained or imprisoned by a court or administrative order.
- People who are under compulsory psychiatric treatment.
- People who are under a legal protection or guardianship order.
- People who are not able to give informed consent.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christophe AUBE, Pr, University Hospital, Angers
Phone: +33(0)24-135-4281
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall patient satisfaction
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.